The aftermath of fraud

In wake of Poehlman affair, academics, journals assess damage control

Written byDoug Payne
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The admission of widespread data fabrication by Eric Poehlman, a well known nutrition researcher, as part of a plea bargain last week has sparked a discussion of about how journals can handle such impropriety.

Poehlman's work was cited widely; the top 10 most-cited of his more than 200 papers have been cited an average of 125 times each. One of those top 10, a 1995 Annals of Internal Medicinepaper that was retracted last year was cited more than 150 times.

"The realization that this work included false statements will force me to re-evaluate how the findings from my research are interpreted," said Wayne W. Campbell of Purdue, in Lafayette, Ind., who has cited Poehlman and called the situation "very disturbing."

"I have followed his research with great interest over the years and used it as part of the foundation for some of my research," Campbell told The Scientist via E-mail. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies